1206 ET - Rocket Pharmaceuticals will likely continue to make slow progress over the course of this year, giving shares a boost, Cantor Fitzgerald analyst Josh Schimmer says in a note. Investors have generally turned away from the gene therapy field due to setbacks related to capsid technology, Schimmer says. But "hope is not lost, certainly for RCKT," he says. The company is addressing significant unmet medical needs as it moves forward with three late-stage programs, he says, noting he continues to hold the management team in high regard. "The company isn't out of the woods, but success with any of its cardio programs would likely drive shares considerably higher from current levels," he says, reiterating his overweight rating on the stock. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

January 02, 2026 12:06 ET (17:06 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.